Pre-submission meeting with US FDA for heart failure
Filed with ASX · · 2 pages · English
Story so far
Earlier from EchoIQ
- The First Step in EIQs US Market Commercialisation Strategy
- S&P DJI Announces December 2024 Quarterly Rebalance
- EIQ signs integration agreement with Flagship US Hospital
- US Based CEO Appointed to Execute Commercialisation Strategy
- Major Milestone Achieved with FDA Clearance for EchoSolv AS
Later from EchoIQ
- Response to ASX Query Letter
- $1.26M R&D tax incentive received
- Appendix 4D 31 December 2024
- Strong Progress in First Two Months of CY25 Achieved
- Investor Webinar Presentation
Follow EchoIQ into a list and get an email when it puts out news.
Follow EchoIQ